# Compass Pathways

announced in February 2026 that its second Phase 3 trial (COMP006) of COMP360 synthetic psilocybin met its primary endpoint in treatment-resistant depression, building on its first positive Phase 3 result.

Source: https://en.bioecon.ru/companies/compass-pathways/
Updated: 2026-07-04

- Country: United Kingdom
- Ticker: CMPS

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $150 million financing in February 2026 and $200 million in warrant exercises reported in 2026, with total funding approximately $948.7 million reported as of October 2024 | https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Highlights/default.aspx, https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm |
| Capacity | The company is working on the scalability and commercial viability of manufacturing methods and investigating the addition of commercial manufacturing capacity in the U.S. | https://content.edgar-online.com/ExternalLink/EDGAR/0001816590-26-000020.html?dest=cmps-20251231_htm&hash=4bd213ae6637fb8d386b1b55da9a9a90188198c6f222ab4ef4c87f6ffd588266 |
| Certification | Breakthrough Therapy designation from the U.S. FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK for COMP360 in treatment-resistant depression | https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Highlights/default.aspx, https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile/, https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/, https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm |
| Regulatory approval | Rolling New Drug Application (NDA) submission and review with the U.S. FDA is underway, with final submission expected in Q4 2026; COMP360 has not yet received marketing approval | https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Highlights/default.aspx, https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile/, https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm |
| Production site | The company is developing manufacturing processes for COMP360 but no specific production sites are explicitly named as active for commercial production [medium confidence] | https://content.edgar-online.com/ExternalLink/EDGAR/0001816590-26-000020.html?dest=cmps-20251231_htm&hash=4bd213ae6637fb8d386b1b55da9a9a90188198c6f222ab4ef4c87f6ffd588266 |
| Headcount | 156 employees as of December 31, 2025 | https://www.marketscreener.com/news/compass-pathways-2025-annual-report-ce7e50dddd8ff425 |
| Revenue | The company reports net income/loss rather than revenue; reported a net income of $91.2 million for Q1 2026 and a net loss of $162.6 million for the first half of 2026 | https://s204.q4cdn.com/927483861/files/doc_news/Compass-Pathways-Announces-First-Quarter-2026-Financial-Results-and-Business-Highlights-2026.pdf, https://www.sec.gov/Archives/edgar/data/1816590/000181659026000059/q22026pressrelease.htm |

Independent sources: content.edgar-online.com, marketscreener.com, s204.q4cdn.com, sec.gov

## Technologies

- [Psychedelic medicine & neuropsychiatric biologics](https://en.bioecon.ru/technology/psychedelic-medicine-neuropsychiatric-biologics/)